SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Huth who wrote (79)11/4/1998 1:38:00 PM
From: Richard Huth  Respond to of 1386
 
I promised to post the information about the ACM conference on Dec.,5.
Prof. Raphael Mechoulam ia announced as special guest. As far as I am informed he will talk about Hu211.

Other speakers invited are all European, subjects: Cannabis and cannabinoids for treatment of MS, pain relief for paraplegics and some less interesting topics.

Richard



To: Richard Huth who wrote (79)11/4/1998 8:51:00 PM
From: Rick Strange  Read Replies (1) | Respond to of 1386
 
Richard,
I believe that the $2.6 million milestone payment that Ariella taked about is linked to first European approval. Aside from the fact that the FDA has approved Lotemax and Alrex, the FDA has no voice in this matter.



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News